medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2003, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2003; 1 (1)

Oral ivermectin: A five years experience. Report of 34 cases of cutaneous parasitosis: scabies, crusted scabies, larva migrans, gnathostomiasis, pediculosis and demodecidosis

Arenas R, Ruiz-Esmenjaud J, Morales-Chávez CE, Ablanedo-Terrazas Y, Rodríguez-Álvarez M

Language: Spanish
References: 52
Page: 20-29
PDF size: 374.33 Kb.


ABSTRACT

Background: Ivermectin is a safe, effective and easily administrated antiparasitic drug in skin diseases, such as scabies, Larva Migrans syndrome and pediculosis. Objective: To corroborate the efficacy and safety ofivermectin in different cutaneous parasi tosis.Methods. From June 1997 till July 2002, we studied 34 cases with cutaneous parasitic in fections: scabies (11), 3 with crusted scabies; Larva Migrans syndrome (9), 7 with gnathost omiasis; de modecidosis (2) and pediculosis (12), all of which were treated with a singledose of oral ivermectin, 200 µg/kg of body weight. Results: Of the 34 patients, 16 (47%) we remen, and 18 (53%) were women. Ageranged from 5 to 61 years (average 30.7). The average time of on set was 13.4 months. The average initial do se of ivermectin was 12.8 mg. A completere mission was observed in 27 patients (79.4%), five partial remission (14.7%) and failure in two (5.8%). Ni ne teen patients (55.8%) had re mission with one do se, and 9 (27.3%) needed a second one; from the se patients, 8 (88.9%) had total remission of the skin disease. conclusions: Ivermect in is an effective and safe drug in the treatment of scabies, in cluding crusted scabies, Larva Migrans syndrome and pediculosis. We didn’t find any important secondary effects.


REFERENCES

  1. Pear son RD. “Agents active against parasites and Pneumocystis carinii”. En: Mandell GL, Benett JE, Dolin R, editors. Mandell, Douglas and Benett’s Principles and practice of infectous diseases. 4th ed. New York. Churchill Livingstone. 2000: 505-539

  2. Tracy JW, Webster LTJ. “Drugs used in the chemotherapy or helminthiasis”. En: Hardman JG, Limbird LE. Goodman & Gilman’s The pharmacological basis of therapeutics. 10th ed. New York. Mc Graw-Hill, 2001: 1121-1140

  3. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. N Engl J Med 1995;333[1]: 6-7, 26-30

  4. Njoo FL, Beek WMJ, Keukens HJ, Van Wilgenburg H, Oosting J, Stillma JS et al. Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. Am J Trop Med Hyg 1995; 52 (1): 94-97

  5. Lui LX, Weller PF. Antiparasitic drugs. N Engl J Med 1996; 334 (18), 1178-1184

  6. Dull HB, Meredith SEO. The Mectizan Donation Programme-a 10-year report. Ann Trop Med Paras 1998; 92 (Supp. 1): S69-S71

  7. Stuart L. Ivermectin approved for strongyloidiasis and onchocerciasis. JAMA 1997; 277 (9), 703

  8. Awadzi K, Opoku NO, Addy ET, Quartey BT. The chemotherapy of onchocerciasis XIX: the clinical and laboratory tolerance of high dose ivermectin. Trop Med Pa ra si tol 1995; 46: 131-137

  9. El mogy M, Fayed H, Marzok H, Rashad A. Oral ivermectin in the treatment of scabies. Int J Dermatol 1999; 38: 926-930

  10. Caumes E, Datry A, Paris L, Danis M, Gentilini M. Efficacy of ivermectin in the therapy of cutaneous larva migrans (letter). Arch Dermatol 1992; 128: 994-995

  11. Caumes E, Carriere J, Datry A, Gaxotte P, Danis M, Gentilini M. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg 1993; 49 (5): 641-644

  12. Barbosa LF, Leal AS, Alvimar FJ, Melo-Monteiro C. Tratamento da sarna crostosa com ivermectina. An Bras Dermatol, Rio de Janeiro 1999; 74 (2): 175-177

  13. Chosidow O. Scabies and pediculosis. Lancet 2000; 355: 819-826

  14. Chappuis F, Farinelli T, Loutan L. Ivermectin treatment for a traveler who returned from Peru with cutaneous gnathostomiasis. Clin Inf Dis 2001; 33: e17-e19.

  15. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodecidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 1999; 41: 775-777

  16. Glaziou P, Nyguyen LN, Moulia-Pelat JP, Cartel JL, Martin PMV. Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Trop Med Parasitol 1994; 45: 253-254

  17. Burkhart CN, Burkhart CG. Another look at ivermectin in the treatment of scabies and head lice (letter). Int J Dermatol 1999; 38: 235

  18. Bouchard O, Houzé S, Schiemann R, Durand R, Ralaimazava P, Ruggeri C et al. Cutaneous larva migrans in travelers: a prospective study, with asessment of therapy with ivermectin. Clin Inf Dis 2000; 31: 493-498

  19. Youssef MYM, Sadaka HAH, Eissa MM, El-Ariny AF. Topical application of iver mectin for human ectoparasites. Am J Trop Med Hyg 1995; 53 (6): 652-653

  20. Yeruham I, Hadani A. Control of human scabies by topical application of ivermectin. Ann Trop Med Paras 1998; 92 (5): 627-629

  21. Macotela-Ruiz E, Peña-González G. Tratamiento de la escabiasis con ivermectina por vía oral. Gac Med Mex 1993; 129 (3): 201-205

  22. Chouela EN, Abeldaño AM, Pellerano G, La Forgia M, Papale RM, Garsd A, Balian MC, Battista V, Poggio N. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol 1999; 135: 651-655

  23. Giudice P. Ivermectin. A new therapeutic weapon in dermatology? (editorial). Arch Dermatol 1999; 135: 705-706

  24. Giudice P. Ivermectin in scabies. Curr Op Inf Dis 2002; 15: 123-126

  25. Aubin F, Humbert P. Ivermectin for crusted (norwegian) scabies. N Eng J Med 1995; 332 (9): 612

  26. Jarami llo-Ayerbe F, Berrío-Muñoz J. Ivermectin for crusted norwegian scabies in duced by use of topicalste roids. Arch Dermatol 1998; 134: 142-144

  27. Caumes E, Carriere J, Guermonprez G, Bricaire F, Danis M, Gentilini M. Dermatoses associated with travel to tropical countries: a prospective study of diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Inf Dis 1995; 20: 542-548

  28. Jelinek T, Maiwald H, Nothdruft HD, Löscher T. Cutaneous larva migrans in travelers: synopsis of histories, symptoms, and treatment of 98 patients. Clin Inf Dis 1994; 19: 1062-1066

  29. Caumes E. Treatment of cutaneous larva migrans. Clin Inf Dis 2000; 30: 811-814

  30. Isoda K-I, Shimizu M, Sonobe K. Human gnathostomiasis: successful removal of Gnathostoma hispidum. Int J Dermatol 1992; 31(5):175-177

  31. Magaña M, Messina M. Dermato patología de la gnathostomosis. Acta Dermatológica & Dermatopatología 2001; 1 (1 y 2): 15-19

  32. Nontasut P. “Treatment of human gnathostomosis in Thailand”. En: Proceedings of the first international meeting on Gnathosthomosis. Culiacán, Sinaloa, México. March 14-16, 2002: 54-56

  33. Roberts RJ. Headlice. N Eng J Med. 2002; 346 (21): 1645-1650

  34. Pérez Pólito A, Chávez G, Arenas R. Pediculosis de la cabeza. Estudio comparativo en 61 pacientes tratados con trimetoprim/sulfametopirazina vs trimetoprim/sulfametoxazol. Dermatología Rev Mex 1989; 33 (5): 298-299

  35. Petri WA Jr. Chapter 44: “Antimicrobial agents”. En: Hardman JG, Limbird LE, editors. Good man & Gilman’s The pharmacological basis of therapeutics. McGraw-Hill, New York, 2001: 1171-1188

  36. Elston DM. Controversies concerning the treatment of lice and scabies. J Am Acad Dermatol. 2002; 46: 794-796

  37. Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case con trol study using standarizad skin-surface biopsy. Br J Dermatol 1993; 128: 650-659

  38. Jurado F, Gutiérrez R. Demodexfolliculorum: ¿ácaro saprobio o patógeno cutáneo? Revisión del tema. Dermatología Rev Mex 2002; 46 (3): 121-126

  39. Hoekzema R, Hulsebosch HJ, Bos JD. Demodecidosis or rosacea: what did we treat? Br J Dermatol 1995; 133: 294-299

  40. Brown S, Bacher J, Brandy W. Treatment of ectoparasitosis infections: review of the English language literature, 1982-1992. Clin Infect Dis 1995; 20 (Suppl. 1): S104-S109

  41. Meinking TL, Entzel P, Villar ME, Vicaria M, L mard G, Porcelain SL. Comparative efficacy of treatments for pediculosis capitis infestations. Arch Dermatol 2002; 137: 287-292

  42. Dodd CS. Interventions for treating head lice (Cochrane review). The Cochrane Library 2002. Issue 4. Oxford Update Software (4)

  43. Usha V, Golopalakrishhnan TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236-240

  44. Arenas R. Dermatología. Atlas, diagnóstico y tratamiento. México. McGraw-Hill-Interamericana. 1996: 395-397

  45. Parish LCh, Witkowski JA. The saga of ectoparasitoses: scabies and pediculosis. Intern J Dermatol 1999; 38: 432-433

  46. Victoria J, Trujillo R. Topical ivermectin: a new successful treatment for scabies. Pediatr Dermatol 2001; 18: 63-65

  47. Bauer J, Blum A, Sonnichsen K et al. Nodular scabies detected by computed dermatoscopy. Dermatology 2001; 203: 190-191

  48. Leppard B, Naburi AE. The use of ivermectin in controling an outbreak of scabies in a prison. Br J Dermatol 2000; 143: 520-523

  49. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies (letter). Lancet 1997; 349: 1144-1145

  50. Diazgranados JA, Costa JL. Deaths after ivermectin treatment (letter). Lancet 1997; 349: 1698

  51. Reintjes R, Hoek C. Deaths associated with ivermectin for scabies (letter). Lancet; 1997: 350: 215

  52. Waikagul J, Dekumyoy P, Visetsuk K, Nontasut P. “IgG levels of gnathosthomiasis patients after albendazol and ivermectin treatment”. En: Proceedings of the first in ternational meeting on Gnathosthomosis. Culiacán, Sinaloa, México. March 14-16, 2002: 54-56




2020     |     www.medigraphic.com